Drugs / CHT102
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06760364 | Dec 2024 → Dec 2027 expected | — | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06717022 | May 2024 → Jun 2026 overdue | neoplasm | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHT 102 | “CHT 102 : MSLN UCAR-T.” NCT06760364 ↗ |
| Modality | Cell therapy | “Universal Chimeric Antigen Receptor T-Cell Immunotherapy(U CAR-T)” NCT06717022 ↗ |
| Route | Other | “UCAR-T cells were transfused three times” NCT06717022 ↗ |
| Target | MSLN | “MSLN-targeting Universal Chimeric Antigen Receptor T-Cell Immunotherapy(U CAR-T)” NCT06717022 ↗ |